Back to results

RecruitingPhase 3

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

NCT06947941

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Local Institution - 0042

Gilbert, Arizona, United States

+19 additional locations

Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com

855-907-3286 Clinical.Trials@bms.com

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2026-03-25
Enrollment: 325 participants
Sponsor: Bristol-Myers Squibb
Purpose: treatment

Locations (20)

Local Institution - 0042Gilbert, Arizona, United States
Inland Psychiatric Medical Group.Chino, California, United States
Local Institution - 0001Naples, Florida, United States
Local Institution - 1401Naples, Florida, United States
Local Institution - 0043Shaker Heights, Ohio, United States
Local Institution - 0020Macquarie Park, New South Wales, Australia
Local Institution - 0052Nedlands, Western Australia, Australia
Local Institution - 0027Whitby, Ontario, Canada
Local Institution - 0025Montreal, Quebec, Canada
Local Institution - 0040Suita, Osaka, Japan
Local Institution - 0035Nankoku-shi, Japan
Local Institution - 0034Osaka, Japan
Local Institution - 0005Exeter, Devon, United Kingdom
Local Institution - 0018Saint Leonards-on-Sea, East Sussex, United Kingdom
Local Institution - 0023London, England, United Kingdom
Local Institution - 0015Oxford, Oxfordshire, United Kingdom
Local Institution - 0009Chertsey, Surrey, United Kingdom
Local Institution - 0017Sheffield, Yorkshire and the Humber, United Kingdom
Local Institution - 0024London, United Kingdom
Local Institution - 0004Motherwell, United Kingdom